Resources
About Us
Rapid Diagnostic Kits Market for Indian Ocean Region Countries (France, India, Australia, Indonesia, Singapore, Sri Lanka, Madagascar) by Product (Professional, OTC), Platform (Immunoassay, Molecular), Application (Infectious Diseases, Cardiac, Urinalysis, Cholesterol), End User (Hospital, Diagnostic Lab) - Forecast to 2029
Report ID: MRHC - 104734 Pages: 145 Jan-2023 Formats*: PDF Category: Healthcare Delivery: 2 to 4 Hours Download Free Sample ReportThe Rapid Diagnostic Kits Market for Indian Ocean Region Countries is expected to register a CAGR of 1.6% from 2022 to 2029 to reach $1.75 billion by 2029. The rapid diagnostics kits market for Indian Ocean region countries covers professional kits and OTC kits offered by key companies in the market to hospitals, clinical laboratories, and home care settings for the qualitative and quantitative detection of specific antigens, antibodies, genetic material, or proteins associated with a particular health condition or disease, helping uncover the underlying mechanisms of diseases and enabling doctors and healthcare workers to make crucial medical decisions. These test kits provide diagnostic results expeditiously (within 1 hour). For the scope of this report, the Indian Ocean region countries include France, India, Australia, Singapore, Indonesia, Madagascar, Mauritius, Réunion, Comoros, Mayotte, and Seychelles.
The growth of this market is driven by the growing demand for PoC diagnostics, the high prevalence of chronic diseases coupled with the increasing geriatric population, the growing prevalence of infectious diseases, the increasing need for rapid decision-making, and the outbreak of the COVID-19 pandemic. Moreover, emerging markets are expected to offer growth opportunities for the players operating in the rapid diagnostic kits market in Indian Ocean region countries. However, variance in test results is a restraining factor for the growth of this market. Additionally, the reluctance to change the existing diagnostic practices is a major challenge for market growth.
Click here to: Get Free Request Sample Pages of this report
Diagnostic tests play a crucial role in the medical care of patients with infections. Usual methods for detecting specific pathogens are generally time-consuming and expensive and require complex analytical instruments and skilled technicians. Also, rapid diagnostic tests are in demand as they can diagnose infectious diseases early, which helps prevent their spread. Rapid diagnostic kits for diagnosing infectious diseases are in high demand in the in-vitro diagnostics (IVD) industry due to the increasing awareness regarding infectious diseases in developing countries, expanding test menus, and advancements in molecular testing and lab-on-chip technology. As the demand for rapid diagnostic kits increases, manufacturing companies compete to develop next-generation rapid diagnostics platforms that are faster, easier to use, and more reliable.
In recent years, the incidence of infectious diseases has increased considerably. For instance, In India, every year, 30 million new cases of sexually transmitted diseases (STDs) and reproductive tract infections (RTIs) are reported. Also, the prevalence of HIV in the population aged 15–49 years is 0.2%. Although the prevalence rate is extremely low, it translates to 2.1 million people due to India’s high population. In addition to this, Indonesia has a high prevalence of tuberculosis. According to the WHO, in 2020, Indonesia accounted for 8.4% of all estimated tuberculosis cases globally. Hence, the growing incidence of infectious diseases further boosted the demand for rapid diagnostic kits to diagnose and manage various infectious diseases. Therefore, looking at the overall scenario, the growing prevalence of infectious diseases is estimated to drive the growth of the rapid diagnostic kits market in Indian Ocean region countries.
Professional Kits Generated Larger Proportion of Revenue Compared to OTC Kits in 2022
The professional kits segment is expected to account for the larger share of the rapid diagnostic kits market in Indian Ocean region countries in 2022. The large market share of this segment is attributed to the availability of disease-specific assays for the early diagnosis of chronic diseases, technological advancements in rapid diagnostics, and the high awareness of professional rapid diagnostic kits.
Immunoassays to Dominate the Market
The immunoassays segment is expected to account for the largest share of the rapid diagnostic kits market in Indian Ocean region countries in 2022. The large market share of this segment is mainly attributed to the high prevalence of chronic and infectious diseases, technological innovations, and the advantages of rapid immunoassay tests, such as cost-effectiveness and at-home testing.
Infectious Diseases Segment to Register Largest Share in the Rapid Diagnostics Kits Market for Indian Ocean Region Countries in 2022
The infectious diseases testing segment is expected to account for the largest share of the rapid diagnostic kits market for Indian Ocean region countries in 2022. The high prevalence of target diseases and outbreaks of infectious diseases and the rise in the awareness and adoption of self-testing kits for infectious diseases are supporting the large market share of this segment.
Hospital & Clinics Segment to Dominate the Market in 2022
The hospital & clinics segment is expected to account for the largest share of the rapid diagnostic kits market in Indian Ocean region countries in 2022. The high rate of hospitalizations due to various diseases, the rising geriatric population, and increased healthcare access & expenditure are the primary factors contributing to the largest share of the market.
India: Fastest Growing Geography
India is expected to be the fastest-growing country during the forecast period. Factors driving the growth of this country include the rising prevalence of chronic diseases and initiatives taken by the government to promote health awareness in the country. According to National AIDS Control Organisation (NACO), around 6% of the adult population (around 30 million people) in India is diagnosed with reproductive tract infections (RTIs) each year, including sexually transmitted infections (STIs). As rapid diagnostics can facilitate accurate and quick diagnosis and management of diseases, the demand for rapid diagnostic kits in India is expected to grow exponentially in the coming years.
In recent years, government initiatives have increased to promote health awareness in the country. Pradhan Mantri Jan Arogya Yojana, Ayushman Bharat, and Mission Indradhanush are some of the recent initiatives launched by the Government of India to promote health awareness. These initiatives are expected to boost the demand for rapid diagnostic kits leading to the growth of this market.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 3 years. The key players profiled in the rapid diagnostic kits market for Indian Ocean region countries report include Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), ACON Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland).
Scope of the Report
Rapid Diagnostic Kits Market for Indian Ocean Region Countries, by Product
Rapid Diagnostic Kits Market for Indian Ocean Region Countries, by Platform
Rapid Diagnostic Kits Market for Indian Ocean Region Countries, by Application
Rapid Diagnostic Kits Market for Indian Ocean Region Countries, by End User
Rapid Diagnostic Kits Market for Indian Ocean Region Countries, by Geography
Key questions answered in the report:
This report provides an analysis of the rapid diagnostic kits market in Indian Ocean region countries (France, India, Australia, Singapore, Indonesia, Madagascar, Mauritius, Réunion, Comoros, Mayotte, and Seychelles), covering platforms such as immunoassays and molecular detection used for applications such as blood glucose testing, cardiac metabolism testing, infectious diseases testing, coagulation testing, pregnancy & fertility testing, fecal occult testing, hematology testing, tumor/cancer markers testing, drugs of abuse testing, cholesterol testing, and urinalysis. The rapid diagnostics kits covered in this report provide diagnostic results expeditiously (within 1 hour).
The rapid diagnostics kits market for Indian Ocean region countries is projected to reach $1.75 billion by 2029, at a CAGR of 1.6% during the forecast period.
Based on product, the OTC kits segment is expected to show the fastest growth rate in the forecast period. The growth of this segment can be attributed to the rising demand for at-home testing, growing awareness about self-testing among the general population, and the increasing prevalence of diseases that require rapid and effective testing. OTC kits are generally at-home testing kits used for fertility testing, blood glucose monitoring, cholesterol testing, and infectious and chronic disease testing. The home testing kits allow patients to save the time and money required for hospital/lab visits, as these tests can be performed at home, and results can be shared with physicians remotely.
The immunoassays segment is expected to account for the largest share of the rapid diagnostic kits market in Indian Ocean region countries in 2022. Immunoassay-based diagnostic kits are widely used in hospitals, clinical laboratories, and home care for the qualitative and quantitative diagnosis and management of communicable and non-communicable diseases. These are commonly used due to their advantages, such as their one-step process, long shelf life, higher portability & lower costs compared to conventional laboratory-based tests, low sample quantities required for testing, recent technological developments, and the increasing use of lateral flow assay kits that can be used at home. The large market share of this segment is mainly attributed to the growing prevalence of chronic and infectious diseases, technological innovations, and the advantages of rapid immunoassay tests, such as cost-effectiveness and at-home testing.
The tumor/cancer markers testing segment is expected to show the fastest growth rate during the forecast period. The burden of cancer is growing, exerting tremendous economic strain on countries. Nearly 70% of cancer deaths occur in low and middle-income countries (source: WHO). The burden of cancer is large in India, Australia, Singapore, Indonesia, Madagascar, Mauritius, Réunion, Comoros, Mayotte, and Seychelles; for example, in 2020, India reported 1,324,413 new cancer cases and this number is projected to reach 1,692,968 by 2030(source: GLOBOCAN). Furthermore, France reported 467,965 new cancer cases and this number is projected to reach 530,863 by 2030 (source: GLOBOCAN). Early detection is very important in reducing mortality, improving the chances of survival, and saving on treatment costs. Various rapid diagnostic kits are used to detect cancer. It is estimated that the demand for rapid diagnostic kits that support cancer testing will grow significantly in the coming years.
The hospitals & clinics segment is expected to account for the largest share of the rapid diagnostic kits market in Indian Ocean region countries in 2022. Factors attributing to this segment's growth include the rising number of hospitalizations due to various diseases, the increasing geriatric population, and rising healthcare access & expenditure. Hospitals & clinics perform a wide range of tests to diagnose various medical conditions to ensure proper clinical planning of treatment and prevention. The growing demand for point-of-care diagnostics, increasing healthcare expenditure, rising prevalence of healthcare-associated infections (HAIs), and growing number of hospitals and clinics across emerging markets are driving the demand for rapid diagnostic kits used in hospitals & clinics.
The growth of this market is driven by the growing demand for PoC diagnostics, the high prevalence of chronic diseases coupled with the increasing geriatric population, the growing prevalence of infectious diseases, the increasing need for rapid decision-making, and the outbreak of the COVID-19 pandemic. Moreover, emerging countries are expected to offer growth opportunities for the players operating in the rapid diagnostic kits market in Indian Ocean region countries.
Key companies operating in the rapid diagnostic kits market for Indian Ocean region countries are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), ACON Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland).
Published Date: Sep-2024
Published Date: Aug-2024
Published Date: Feb-2024
Published Date: Jan-2024
Please enter your corporate email id here to view sample report.
Subscribe to get the latest industry updates